RecruitingPhase 2NCT06004830

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1

Feasibility, Acceptability, and Preliminary Efficacy of Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: An Open-Label Pilot Study


Sponsor

Yale University

Enrollment

30 participants

Start Date

Nov 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study seeks to determine the feasibility, acceptability, and preliminary efficacy of an intervention consisting of off-label use of a medication with strong efficacy data for alcohol use disorder (AUD) with medical management and a clinical pharmacist-delivered behavioral intervention in reducing alcohol use among individuals with HIV and AUD.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This pilot study is testing whether a medication used off-label (spironolactone) can help people living with HIV who also have an alcohol use disorder reduce their drinking. **You may be eligible if:** - You are 18 or older and living with HIV - You receive care at the Atlanta VA Healthcare System - You have a diagnosed alcohol use disorder (mild, moderate, or severe) - You are taking 5 or more medications - You have a cell phone or reliable contact number **You may NOT be eligible if:** - You are already in a formal alcohol treatment program or on medications for alcohol use - You are pregnant, nursing, or trying to conceive - You have an untreated moderate-to-severe opioid use disorder - You have poor kidney function or high potassium levels - You live outside the state - You take medications that interact with the study drug (such as lithium or digoxin) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSpironolactone

All participants will receive a prescription for spironolactone and will meet with a clinical pharmacist and addiction psychiatrist for further support


Locations(1)

Atlanta VA Medical Center

Decatur, Georgia, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06004830


Related Trials